FIELD: medicine.
SUBSTANCE: it has been suggested to apply CD-25-binding molecules, basiliximab being the representative, to be applied in combination with other medicinal preparation. It is considered to be efficient in treating inflammatory diseases of gastrointestinal tract. Moreover, it has been suggested to apply basiliximab for improving a painful state of gastrointestinal tract.
EFFECT: higher efficiency of application.
9 cl
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF CD25-BINDING MOLECULES FOR TREATMENT OF STEROID-RESISTANT PATIENTS | 2002 |
|
RU2318537C2 |
| NEW INDICATIONS FOR USE IN TREATING ANTIBODIES AGAINST IL-1-BETA | 2014 |
|
RU2698208C2 |
| NOVEL APPLICATION OF IL-1β COMPOUNDS | 2012 |
|
RU2571563C2 |
| RECOMBINED ANTIBODY TO HUMAN INTERLEUKIN 1β | 2001 |
|
RU2264413C2 |
| HUMAN ANTIBODIES TO IL-β1 | 2001 |
|
RU2286351C2 |
| NEW APPLICATION OF IL-1β COMPOUNDS | 2006 |
|
RU2468817C2 |
| ANTIBODIES RAISED TO HUMAN MCP-1 | 2001 |
|
RU2314316C2 |
| THERAPEUTIC BINDING MOLECULES | 2002 |
|
RU2328506C2 |
| IL-18-BINDING PROTEIN (IL-18BP) AND ANTIBODIES IN INFLAMMATORY DISEASES | 2016 |
|
RU2755691C2 |
| IL-18 BINDING PROTEIN (IL-18BP) AND ANTIBODIES IN TREATING INFLAMMATORY DISEASES | 2016 |
|
RU2810206C1 |
